SOURCE: Accelrys


March 16, 2010 08:00 ET

Accelrys Announces Latest Release of Its Leading Discovery Studio® Application for Life Science Researchers

Supports New Scientific Algorithms and Integration With Latest Version of GOLD Docking Program

SAN DIEGO, CA--(Marketwire - March 16, 2010) -  Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific business intelligence software and services, today announced the release of Accelrys Discovery Studio®2.5.5, the most advanced computational chemistry and biology software application for drug discovery available today.

This release, powered by Accelrys Pipeline Pilot, the underlying scientific business intelligence and data pipelining platform, features new algorithmic developments in the protein modeling area, access to the latest version of the popular GOLD docking program (licensed by CCDC), and enhanced usability and performance to meet the demands and challenges of modern drug discovery projects.

New and innovative scientific protocols include a 3D QSAR method and a protocol for calculating residue electrostatic energy for predicting protein stability and thermostability. Additional enhancements include two new user interface Discovery Guides and 64-bit server compatibility that significantly improves the performance of processor-heavy calculations.

The integration of GOLD with Accelrys Discovery Studio creates a powerful synergy between CCDC and Accelrys' well established pedigree of validated modeling methods in Discovery Studio. The strong relationship with CCDC exemplifies Accelrys' strategy in building an ecosystem of partners that are using Accelrys Pipeline Pilot to create solutions that are uniquely tailored to fit their specific research requirements.

Dr. Ramesh Sistla, principal scientist and head of molecular modeling and protein crystallography, Aurigene Discovery Technologies Ltd, commented, "Our choice of GOLD was based on its excellent reviews, great performance in our discovery programs during evaluation, customizable scoring function, and friendly licensing terms. We selected Accelrys Discovery Studio because it offers tight integration with GOLD as well as offering a state of the art application for ligand based drug design, homology modeling and protein crystallography -- all within one slick and customizable interface."

While GOLD provides an in silico tool for accurately screening compounds, the Accelrys Discovery Studio application completes the solution by providing accurate and sophisticated pre- and post-docking capabilities, such as protein preparation, ligand preparation and advanced analytics.

"I'm delighted to be working with Accelrys, with whom the CCDC has a long history of collaboration," said Dr. Colin Groom, executive director of the CCDC. "The widespread use of Accelrys Pipeline Pilot, particularly in the pharmaceutical and biotech industries, makes Accelrys a natural partner for us."

For more information about Discovery Studio 2.5.5 please visit:

For more information on becoming an Accelrys certified partner, click here:

About Accelrys, Inc.
Headquartered in San Diego, California, Accelrys develops scientific business intelligence software and solutions for the life sciences, energy, chemicals, aerospace, and consumer products industries. Customers include many Fortune 500 companies and other commercial entities, as well as academic and government entities. Accelrys has a vast portfolio of computer-aided design modeling and simulation offerings which assist customers in conducting scientific experiments 'in silico' in order to reduce the duration and cost of discovering and developing new drugs and materials. Its scientific business intelligence platform underlies the company's computer-aided design modeling and simulation offerings. The Accelrys platform can be used with both Accelrys and competitive products, as well as with customers' proprietary predictive science products. Its flexibility, ease-of-use and advanced chemical, text and image analysis and reporting capabilities enable customers to mine, aggregate, analyze and report scientific data from disparate sources, thereby better utilizing scientific data within their organizations. For more information about Accelrys, visit

Forward-Looking Statements
This press release contains forward-looking statements. Such statements, including statements relating to the Company's products, their features, and their impact upon our customers' organizations, are subject to risks and uncertainties including, but not limited to, the risk that our products will not be successfully developed, achieve market acceptance, have the anticipated impact upon our customers' organizations, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and any subsequent interim filings. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.